FARALLON CAPITAL MANAGEMENT LLC - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 142 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.

Quarter-by-quarter ownership
FARALLON CAPITAL MANAGEMENT LLC ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$20,943,750
-47.8%
1,875,0000.0%0.10%
-49.5%
Q2 2023$40,125,000
-36.0%
1,875,000
+21.0%
0.21%
-40.1%
Q1 2023$62,682,000
-13.1%
1,550,0000.0%0.35%
-19.3%
Q4 2022$72,106,000
-10.3%
1,550,0000.0%0.43%
-3.4%
Q3 2022$80,399,000
+9.7%
1,550,0000.0%0.44%
+11.2%
Q2 2022$73,269,000
-33.6%
1,550,0000.0%0.40%
-25.0%
Q1 2022$110,329,000
-6.3%
1,550,000
-1.5%
0.53%
-9.4%
Q4 2021$117,691,000
+3.8%
1,573,829
-21.1%
0.59%
+11.2%
Q3 2021$113,336,000
+29.1%
1,995,0000.0%0.53%
+47.8%
Q2 2021$87,800,000
-10.8%
1,995,0000.0%0.36%
-26.8%
Q1 2021$98,393,000
+31.7%
1,995,000
+12.4%
0.49%
+8.9%
Q4 2020$74,728,000
-8.0%
1,775,0000.0%0.45%
-20.1%
Q3 2020$81,260,000
-7.5%
1,775,000
+1.4%
0.56%
-20.1%
Q2 2020$87,868,000
-2.4%
1,750,0000.0%0.70%
-9.1%
Q1 2020$90,003,000
-16.8%
1,750,0000.0%0.77%
+5.9%
Q4 2019$108,115,000
+41.2%
1,750,000
+37.3%
0.73%
+26.3%
Q3 2019$76,555,000
-5.5%
1,274,212
+32.7%
0.58%
+9.7%
Q2 2019$81,005,000
-9.8%
960,000
+2.1%
0.53%
-21.9%
Q1 2019$89,789,000
+37.0%
940,000
+1.6%
0.68%
+40.6%
Q4 2018$65,518,000
-11.6%
925,000
+6.6%
0.48%
+9.6%
Q3 2018$74,137,000
-40.5%
867,500
-19.3%
0.44%
-43.0%
Q2 2018$124,593,000
+68.3%
1,075,000
+17.5%
0.77%
+49.9%
Q1 2018$74,033,000
+36.4%
915,000
-1.1%
0.51%
+16.3%
Q4 2017$54,279,000
+181.3%
925,000
+124.3%
0.44%
+156.4%
Q3 2017$19,297,000412,3330.17%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 1,055,719$35,367,00012.68%
GREAT POINT PARTNERS LLC 828,253$27,746,0005.70%
McClain Value Management LLC 116,153$3,891,0004.80%
Stonepine Capital Management, LLC 231,913$7,769,0004.63%
ARMISTICE CAPITAL, LLC 228,000$7,638,0001.81%
Opaleye Management Inc. 90,000$3,015,0001.78%
Matarin Capital Management, LLC 257,268$8,618,478,0000.97%
HAYS ADVISORY LLC 116,939$3,917,0000.87%
Granahan Investment Management 496,025$16,617,0000.57%
AlphaMark Advisors, LLC 33,000$1,106,0000.57%
View complete list of ENANTA PHARMACEUTICALS INC shareholders